Imaging Biometrics (IB), a leader in advanced neuroimaging solutions, announced an amendment to its distribution agreement with GE HealthCare, expanding access to two innovative offerings: FTB Express maps and QSMetric.
The agreement already includes IB Neuro and Delta T1 maps, widely adopted together to assist clinicians in diagnosing, planning, and monitoring treatment response for brain tumor patients. Delta T1 maps provide rapid, objective delineation of contrast-enhancing regions, while IB Neuro generates standardized (quantitative) MR DSC perfusion images of relative cerebral blood volume (sRCBV), which eliminates manual tissue normalization. These outputs serve as inputs for Fractional Tumor Burden (FTB) maps, which deliver automated visualization of tumor versus non-tumor tissue and treatment effects within enhancing regions. FTB Express accelerates this process, enabling clinicians to quickly access actionable insights for patient care.
QSMetric is a patented quantitative susceptibility mapping software that processes gradient echo brain images to visualize tissue structures and measure susceptibility values. This capability supports a broad range of clinical applications, including targeting for deep brain stimulation (DBS) surgery, neurodegenerative disease assessment, multiple sclerosis, and more.
“We are excited to expand our collaboration with Imaging Biometrics to enable access for our customers to these clinically important capabilities,” GE HealthCare Global MR Visualization Product Manager Katie Anderson said.
